



SUPPORT



TRUST



UNITY



EXCELLENCE

Marin County COVID-19 Pediatric Vaccine Update

April 25, 2022

Marin County Daily COVID-19 Cases


Daily New Confirmed Cases

Case Type Color Legend:

- Reinfection
- Antigen Detected Only (No PCR Test)
- PCR Confirmed

Filter by Case Type:


- Antigen Detected Only (No PCR Test)
- PCR Confirmed
- Reinfection



Case Rate per 100,000 Residents (Age Group)

PCR Positives + Antigen


0-4 5-11 12-18 18+



Case Rate per 100,000 Residents (Age Group)

PCR Positives + Antigen

— 0-4 — 5-11 — 12-18 — 18+



CDC COVID-19 Community Level



COVID-19 County Check

● Low

In Marin County, California, community level is Low.

Level of Community Transmission ● High

Weekly Metrics Used to Determine the COVID-19 Community Level

Case Rate per 100,000 population 154.16

New COVID-19 admissions per 100,000 population 3.7


% Staffed inpatient beds in use by patients with confirmed COVID-19 2.5%

	Low	Moderate	Substantial	High
New cases per 100,000 persons in the past 7 days	<10	10-49.99	50-99.99	≥100
Percentage of positive NAATs tests during the past 7 days	<5%	5-7.99%	8-9.99%	≥10.0%


Hybrid vigor immunity with COVID-19 vaccines

Hybrid vigor can occur when different plant lines are bred together and the hybrid is a much stronger plant. Something similar happens when natural immunity is combined with vaccine-generated immunity, resulting in 25 to 100 times higher antibody responses, driven by memory B cells and CD4⁺ T cells and broader cross-protection from variants.

- Memory B cells ● Antibodies
- CD4⁺ T cells ● CD8⁺ T cells



COVID-19 Vaccine — 6 months to 4 years old




- COVID-19 can cause severe illness in infants and children aged 0–4 years
- During Omicron surge, U.S. infants and children aged 0–4 years were hospitalized at five times the rate of the previous peak (Delta)

Figure. Comparison of Risks of Clinical Outcomes of SARS-CoV-2 Infection in Children Younger Than 5 Years

A Omicron vs Delta cohorts

Outcome	Matched Omicron cohort, No. (%)	Matched Delta cohort, No. (%)	HR (95% CI)
ED visits	4637 (20.36)	5602 (24.60)	0.84 (0.80-0.87)
Hospitalizations	401 (1.76)	741 (3.25)	0.66 (0.58-0.74)
ICU admissions	38 (0.17)	115 (0.51)	0.35 (0.25-0.51)
Mechanical ventilation	10 (0.04)	51 (0.22)	0.15 (0.07-0.33)



COVID-19 Pediatric Vaccine Updates

- Feb.11, 2022 – Pfizer:
 - Studying **3 µg three-dose primary series** for 6 months to 4 years old (next update expected early May)
- Mar. 23, 2022 – Moderna
 - 6 months – under 6 years old: **25 µg two-dose primary series** of mRNA-1273
 - **6 to under 12 years**: Initiated the submission process with the U.S. FDA for an EUA of a **50 µg two-dose primary series** of mRNA-1273
 - Evaluating boosters for all pediatric populations

CDPH Statement on Timeline for COVID-19 Vaccine Requirements in Schools

- FDA has not fully approved COVID-19 vaccines for individuals of all ages within the 7–12 grade span.
- Full approval is a precondition to initiate the rulemaking process to add the COVID-19 as required for in-person school attendance
- California will not initiate the regulatory process for a COVID-19 vaccine requirement for the 2022-2023 school year
- Any vaccine requirements would take effect no sooner than July 1, 2023.

CDPH Statement on Timeline for COVID-19 Vaccine Requirements in Schools

Upon full approval by the FDA, CDPH will consider the recommendations of the Advisory Committee on Immunization Practices (ACIP) of the United States Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) prior to implementing a school vaccine requirement.

Benefits of Pediatric COVID-19 Vaccination

- Reduce risk of COVID-19 infection
- Early evidence that vaccine may reduce risk of long COVID
- Decrease community COVID-19 transmission
- Reduces probability of emergence of new variants
- Decrease disruptions to school / social activities
- Decrease risk of exposing persons at higher risk for severe COVID-19 outcomes (e.g., grandparents)

Thank you

